Peptide Comparison
ImunofanvsLL-37
Synthetic hexapeptide derived from thymopoietin with immunomodulatory, antioxidant, and hepatoprotective properties
Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers
At a Glance
Quick
comparison
Dose Range
Imunofan
50–100 mcg
LL-37
0.5–1.6 mg/mL (topical)
Frequency
Imunofan
Once daily
LL-37
Once daily
Administration
Imunofan
Subcutaneous injection
LL-37
Topical application (wound healing)
Cycle Length
Imunofan
8-12 weeks
LL-37
12+ weeks
Onset Speed
Imunofan
Rapid (hours to days)
LL-37
Moderate (1-2 weeks)
Evidence Level
Imunofan
Limited human trials
LL-37
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Immune
Healing & Recovery
Anti-Aging
Healing
Technical Data
Compound
specifications
Imunofan
Molecular Formula
C36H61N13O10
Molecular Weight
836.0 g/mol
Half-Life
Approximately 2-4 hours (intranasal administration)
Bioavailability
~90-95% (subcutaneous injection)
CAS Number
Not assigned (Russian pharmacopeia compound)
LL-37
Molecular Formula
C205H340N60O53
Molecular Weight
4,493.26 Da
Half-Life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS Number
154947-66-7
Protocols
Dosing
tiers
Imunofan
LL-37
Applications
Best
suited for
Imunofan
Cancer Adjuvant Therapy
Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness.
Chronic Viral Hepatitis
With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery.
Chronic Infections with Immunodepression
Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months.
Oxidative Stress Reduction
The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance.
LL-37
Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Imunofan
Common
- Injection site reaction
- Transient headache
- Nasal irritation (intranasal form)
- Transient mild fever
- Mild fatigue
- Gastrointestinal discomfort (suppository form)
Uncommon
- Allergic reaction
Serious
- Anaphylactic reaction / Severe hypersensitivity
LL-37
Common
- Local site irritation
- Transient stinging or burning
- Mild perilesional erythema
- Increased wound exudate
Uncommon
- Allergic contact reaction
Serious
- Hemolytic activity at systemic concentrations
Research Status
Safety
& evidence
Imunofan
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses.
Contraindications
- xKnown hypersensitivity to imunofan or excipients
- xPregnancy complicated by Rh-conflict (contraindicated)
- xChildren under 2 years of age
- xSevere allergic conditions in acute exacerbation
LL-37
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.
Contraindications
- xKnown hypersensitivity to cathelicidin peptides or formulation components
- xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
- xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
- xSevere renal impairment — peptide clearance may be altered
Decision Guide
Which is
right for you?
Choose Imunofan if...
- Immune system restoration and modulation
- Adjunctive therapy during chemotherapy and radiation
- Support during chronic hepatitis treatment
- Reducing oxidative stress and free radical damage
Choose LL-37 if...
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- Boosting innate immune defense in immunocompromised or aging individuals